Sabinsa and Postbiotics Inc. announce a multinational distribution agreement for PoZibio, a postbiotic ingredient
The agreement includes distribution in the USA, Canada, European Union, and other significant markets such as India and Japan.
Photo © AdobeStock.com/BillionPhotos.com
Sabinsa Corp. (East Windsor, NJ) and Postbiotics Inc. (Winston-Salem, NC) announced a multinational distribution agreement for the postbiotic ingredient, PoZibio, which supports age-related digestive health conditions such as Leaky Gut Syndrome. The agreement includes distribution in the USA, Canada, European Union, and other significant markets such as India and Japan.
According to a press release, PoZibio is a patent-pending postbiotic composition of Lipoteichoic Acid, isolated from the cell walls of a heat-treated strain of Lactobacillus paracasei(Patent Number US 11,622,981 B2). The composition was reportedly discovered by researchers at Wake Forest University College of Medicine, and because of its low dose, heat stability, and neutral flavor profile, PoZibio is suitable for a range of applications such as dietary supplements, medical foods, and dietary supplements.
“The gut-brain axis benefits we have shown from PoZibio are compelling,” said Hariom Yadav, PhD, associate professor of neurosurgery and brain repair and director of the University of Florida’s Center of Microbiome Research, in a press release. Yadav discovered the ingredient during his time at Wake Forest University. “PoZibio has been shown to increase the mucous layer of the gut wall, inhibit age-related inflammation (inflammaging), support cognitive function, and promote muscle and metabolic health, in prior and ongoing research,” he explained.
“I’m pleased to bring forth an ingredient for a condition that is very under addressed in the marketplace,” said Shaheen Majeed, global CEO and managing director of Sabinsa, in a press release. “Additionally, this marks one of the very first partnerships Sabinsa enters into globally, and at its core represents the best of science and functionality.”
“We are pleased to be working with Sabinsa, and believe their global sales organization and manufacturing prowess are perfect complements to our world-class research,” added Doug Lynch, co-founding partner and chief commercial officer of Postbiotics Inc. “This distribution partnership with Sabinsa for will ensure consumer brands of supplements and foods in the United States and beyond will experience the many benefits from postbiotics on improving health and lifespan.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
